Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction
The effects of oral treatment with coenzyme Q10 (120 mg/d) were compared for 28 days in 73 (intervention group A) and 71 (placebo group B) patients with acute myocardial infarction (AMI). After treatment, angina pectoris (9.5 vs. 28.1), total arrhythmias (9.5% vs. 25.3%), and poor left ventricular f...
Saved in:
Published in | Cardiovascular drugs and therapy Vol. 12; no. 4; pp. 347 - 353 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Dordrecht
Springer
01.09.1998
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The effects of oral treatment with coenzyme Q10 (120 mg/d) were compared for 28 days in 73 (intervention group A) and 71 (placebo group B) patients with acute myocardial infarction (AMI). After treatment, angina pectoris (9.5 vs. 28.1), total arrhythmias (9.5% vs. 25.3%), and poor left ventricular function (8.2% vs. 22.5%) were significantly (P < 0.05) reduced in the coenzyme Q group than placebo group. Total cardiac events, including cardiac deaths and nonfatal infarction, were also significantly reduced in the coenzyme Q10 group compared with the placebo group (15.0% vs. 30.9%, P < 0.02). The extent of cardiac disease, elevation in cardiac enzymes, and oxidative stress at entry to the study were comparable between the two groups. Lipid peroxides, diene conjugates, and malondialdehyde, which are indicators of oxidative stress, showed a greater reduction in the treatment group than in the placebo group. The antioxidants vitamin A, E, and C and beta-carotene, which were lower initially after AMI, increased more in the coenzyme Q10 group than in the placebo group. These findings suggest that coenzyme Q10 can provide rapid protective effects in patients with AMI if administered within 3 days of the onset of symptoms. More studies in a larger number of patients and long-term follow-up are needed to confirm our results. |
---|---|
AbstractList | The effects of oral treatment with coenzyme Q10 (120 mg/d) were compared for 28 days in 73 (intervention group A) and 71 (placebo group B) patients with acute myocardial infarction (AMI). After treatment, angina pectoris (9.5 vs. 28.1), total arrhythmias (9.5% vs. 25.3%), and poor left ventricular function (8.2% vs. 22.5%) were significantly (P < 0.05) reduced in the coenzyme Q group than placebo group. Total cardiac events, including cardiac deaths and nonfatal infarction, were also significantly reduced in the coenzyme Q10 group compared with the placebo group (15.0% vs. 30.9%, P < 0.02). The extent of cardiac disease, elevation in cardiac enzymes, and oxidative stress at entry to the study were comparable between the two groups. Lipid peroxides, diene conjugates, and malondialdehyde, which are indicators of oxidative stress, showed a greater reduction in the treatment group than in the placebo group. The antioxidants vitamin A, E, and C and beta-carotene, which were lower initially after AMI, increased more in the coenzyme Q10 group than in the placebo group. These findings suggest that coenzyme Q10 can provide rapid protective effects in patients with AMI if administered within 3 days of the onset of symptoms. More studies in a larger number of patients and long-term follow-up are needed to confirm our results. The effects of oral treatment with coenzyme Q10 (120 mg/d) were compared for 28 days in 73 (intervention group A) and 71 (placebo group B) patients with acute myocardial infarction (AMI). After treatment, angina pectoris (9.5 vs. 28.1), total arrhythmias (9.5% vs. 25.3%), and poor left ventricular function (8.2% vs. 22.5%) were significantly (P < 0.05) reduced in the coenzyme Q group than placebo group. Total cardiac events, including cardiac deaths and nonfatal infarction, were also significantly reduced in the coenzyme Q10 group compared with the placebo group (15.0% vs. 30.9%, P < 0.02). The extent of cardiac disease, elevation in cardiac enzymes, and oxidative stress at entry to the study were comparable between the two groups. Lipid peroxides, diene conjugates, and malondialdehyde, which are indicators of oxidative stress, showed a greater reduction in the treatment group than in the placebo group. The antioxidants vitamin A, E, and C and beta-carotene, which were lower initially after AMI, increased more in the coenzyme Q10 group than in the placebo group. These findings suggest that coenzyme Q10 can provide rapid protective effects in patients with AMI if administered within 3 days of the onset of symptoms. More studies in a larger number of patients and long-term follow-up are needed to confirm our results. |
Author | RASTOGI, A MEHROTRA, S. K CHOPRA, R. K MITTAL, A SHARMA, J. P SINGH, R. B SHUKLA, P. K WANDER, G. S KAPOOR, R |
Author_xml | – sequence: 1 givenname: R. B surname: SINGH fullname: SINGH, R. B organization: Heart Research Laboratory, Centre of Nutrition Medical Hospital and Research Centre, Moradabad, India – sequence: 2 givenname: G. S surname: WANDER fullname: WANDER, G. S organization: Heart Research Laboratory, Centre of Nutrition Medical Hospital and Research Centre, Moradabad, India – sequence: 3 givenname: A surname: RASTOGI fullname: RASTOGI, A organization: Heart Research Laboratory, Centre of Nutrition Medical Hospital and Research Centre, Moradabad, India – sequence: 4 givenname: P. K surname: SHUKLA fullname: SHUKLA, P. K organization: Heart Research Laboratory, Centre of Nutrition Medical Hospital and Research Centre, Moradabad, India – sequence: 5 givenname: A surname: MITTAL fullname: MITTAL, A organization: Heart Research Laboratory, Centre of Nutrition Medical Hospital and Research Centre, Moradabad, India – sequence: 6 givenname: J. P surname: SHARMA fullname: SHARMA, J. P organization: Heart Research Laboratory, Centre of Nutrition Medical Hospital and Research Centre, Moradabad, India – sequence: 7 givenname: S. K surname: MEHROTRA fullname: MEHROTRA, S. K organization: Heart Research Laboratory, Centre of Nutrition Medical Hospital and Research Centre, Moradabad, India – sequence: 8 givenname: R surname: KAPOOR fullname: KAPOOR, R organization: Heart Research Laboratory, Centre of Nutrition Medical Hospital and Research Centre, Moradabad, India – sequence: 9 givenname: R. K surname: CHOPRA fullname: CHOPRA, R. K organization: Heart Research Laboratory, Centre of Nutrition Medical Hospital and Research Centre, Moradabad, India |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1591462$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9825179$$D View this record in MEDLINE/PubMed |
BookMark | eNo90E1r3DAQBmAREtLNx7mngg6lpzodSbZk5baEtgkEQkpyXkYfpgqytLFkwu6vj0OXnubwPu_AzBk5Tjl5Qj4zuGLAxY_1NQNQSraSSeDdEVmxTolG8ZYdkxVoDo3gID-Rs1JeYKFa96fkVPe8Y0qvSPqDyeUx7L37Tl2eTfSNiSE5uo1ovcmNzalOOUbvaJ0CRpoHarNP-93o6SMDGhLdYg0-1ULfQv1L0c7V03GXLU7uoxHSgJOtIacLcjJgLP7yMM_J86-fTze3zf3D77ub9X1jec9q07lukMtNLTohLdNSdIPjrbaGKS4QBgHg0ah-YcKotjMGtDRGAcOWOSPOybd_e7dTfp19qZsxFOtjxOTzXDYKQPY9sAV-OcDZjN5ttlMYcdptDg9a8q-HHIvFOEyYbCj_Ges0ayUX70ozdt8 |
CODEN | CDTHET |
CitedBy_id | crossref_primary_10_4163_jnh_2013_46_3_218 crossref_primary_10_1016_j_pop_2010_02_010 crossref_primary_10_1007_s12012_009_9051_5 crossref_primary_10_1016_j_pharmthera_2009_07_003 crossref_primary_10_1016_j_mcna_2004_02_003 crossref_primary_10_1038_s41598_023_35896_w crossref_primary_10_1152_physrev_00004_2002 crossref_primary_10_1080_01932691_2018_1515023 crossref_primary_10_3390_pharmaceutics12040332 crossref_primary_10_3945_jn_111_155341 crossref_primary_10_1016_j_ymben_2011_09_009 crossref_primary_10_1016_j_jacc_2020_12_009 crossref_primary_10_1016_S0306_9877_03_00232_9 crossref_primary_10_3390_ijms151120169 crossref_primary_10_1016_j_wneu_2024_04_141 crossref_primary_10_1089_act_2006_12_268 crossref_primary_10_1007_s00253_005_1946_x crossref_primary_10_2131_jts_32_437 crossref_primary_10_1002_jnr_10579 crossref_primary_10_3390_antiox11071360 crossref_primary_10_1016_S0891_5849_02_00916_4 crossref_primary_10_1016_j_ptdy_2016_03_007 crossref_primary_10_1016_S0167_5273_98_00323_4 crossref_primary_10_1016_S0306_9877_02_00226_8 crossref_primary_10_1007_s10616_010_9330_9 crossref_primary_10_1111_j_0889_7204_2001_0990801_x crossref_primary_10_1007_s10787_019_00572_x crossref_primary_10_1021_jf800035f crossref_primary_10_1016_j_arcmed_2015_08_006 crossref_primary_10_1089_acm_2006_6206 crossref_primary_10_1016_j_bbadis_2020_165768 crossref_primary_10_1097_00000446_200304000_00022 crossref_primary_10_12968_npre_2013_11_12_602 crossref_primary_10_1038_s41569_018_0074_0 crossref_primary_10_1100_2012_792756 crossref_primary_10_1111_j_1751_7117_2008_00014_x crossref_primary_10_5012_bkcs_2013_34_4_1257 crossref_primary_10_1155_2013_437613 crossref_primary_10_1161_RES_0000000000000110 crossref_primary_10_3390_ijms12129216 crossref_primary_10_1177_1753944717743920 crossref_primary_10_1111_j_1525_1497_2004_30090_x crossref_primary_10_1016_S0753_3322_04_80011_8 crossref_primary_10_1002_med_21732 crossref_primary_10_1016_S0021_9150_99_00273_7 crossref_primary_10_3390_cells11111855 crossref_primary_10_1002_biof_5520180220 crossref_primary_10_1111_bju_12485 crossref_primary_10_1097_00045391_200107000_00009 crossref_primary_10_1016_j_lfs_2019_116641 crossref_primary_10_1016_S0140_6736_05_76585_5 crossref_primary_10_1016_j_cca_2007_01_025 crossref_primary_10_2131_jts_34_389 crossref_primary_10_3390_antiox7080099 crossref_primary_10_1002_biof_5520180210 crossref_primary_10_1162_NECO_a_00659 crossref_primary_10_2165_00129784_200202030_00005 crossref_primary_10_1054_jelc_2001_22032 crossref_primary_10_1097_00005082_200207000_00003 crossref_primary_10_1089_107628003322017332 crossref_primary_10_1186_s12872_024_03729_x crossref_primary_10_1016_j_yrtph_2006_05_006 crossref_primary_10_12968_bjca_2013_8_11_525 crossref_primary_10_3389_fcvm_2022_857364 crossref_primary_10_1038_ijo_2008_265 crossref_primary_10_1016_j_neurobiolaging_2014_03_032 crossref_primary_10_1016_j_matlet_2013_07_057 crossref_primary_10_1016_j_tcm_2022_02_005 crossref_primary_10_1016_S0753_3322_01_90016_2 crossref_primary_10_1155_2016_9152732 crossref_primary_10_1111_j_1520_037X_2000_80355_x crossref_primary_10_1194_jlr_M009449 crossref_primary_10_1016_j_jtemb_2014_11_006 crossref_primary_10_1080_13590849961636 crossref_primary_10_1038_jhh_2015_42 crossref_primary_10_1146_annurev_nutr_071714_034258 crossref_primary_10_3390_ijms161126059 crossref_primary_10_1007_s13596_019_00360_6 crossref_primary_10_1016_S0167_5273_02_00308_X crossref_primary_10_1016_j_clinbiochem_2004_02_008 crossref_primary_10_1097_01_crd_0000091839_22076_f4 crossref_primary_10_1016_j_nut_2011_06_004 |
ContentType | Journal Article |
Copyright | 1999 INIST-CNRS |
Copyright_xml | – notice: 1999 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1023/A:1007764616025 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1573-7241 |
EndPage | 353 |
ExternalDocumentID | 9825179 1591462 |
Genre | Clinical Trial Randomized Controlled Trial Journal Article |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 7X7 88E 8AO 8FI 8FJ 8FW 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKAS AAKSU AANXM AANZL AAPBV AARHV AARTL AATVU AAUYE AAWCG AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFLS ABFTV ABHLI ABHQN ABIPD ABJOX ABKAS ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTMW ABULA ABUWG ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHXU ACIGE ACIPQ ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACUDM ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADKNI ADKPE ADMDM ADRFC ADTIX ADURQ ADYFF ADZCM ADZKW AEBTG AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESTI AETLH AEVTX AEXYK AFEXP AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMYLF AMYQR ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBAFP BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI CAG COF CS3 CSCUP DL5 DNIVK DU5 EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IMOTQ IPNFZ IQODW ITM IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH KSO L7B LAK LLZTM LSO M1P M4Y MA- N2Q NB0 NDZJH NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQEST PQQKQ PQUKI PRINS PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNX SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK8 YFH YLTOR Z45 Z7U Z82 Z87 Z8O Z8U Z8V Z91 ZGI ZMTXR ZOVNA ~EX AACDK AAEOY AAJBT AASML AATNV ABAKF ABJNI ABTKH ABWNU ACAOD ACDTI ACZOJ ADTPH AEFQL AEMSY AESKC AEVLU AFBBN AGQEE AGRTI AIGIU AJOOF ALIPV AMXSW AOCGG CCPQU CGR CUY CVF DDRTE DPUIP ECM EIF HMCUK IKXTQ IWAJR NPM NPVJJ SNPRN SOHCF 7X8 |
ID | FETCH-LOGICAL-c281t-5d5f66464ad36c19635fd249cb1723a0f300eab785f63b745bb096bb701a41db3 |
ISSN | 0920-3206 |
IngestDate | Sun Sep 29 07:34:58 EDT 2024 Sat Sep 28 07:32:46 EDT 2024 Thu Nov 24 18:30:42 EST 2022 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Human Oxidative stress Infarct Acute Treatment efficiency Cardioprotective agent Vitamin Oral administration Cardiovascular disease Controlled therapeutic trial Antioxidant Coronary heart disease Myocardial disease Long term Coenzyme Chemotherapy Randomization Treatment Ubiquinone Placebo Double blind study Myocardium |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c281t-5d5f66464ad36c19635fd249cb1723a0f300eab785f63b745bb096bb701a41db3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-News-3 content type line 23 |
PMID | 9825179 |
PQID | 70068801 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_70068801 pubmed_primary_9825179 pascalfrancis_primary_1591462 |
PublicationCentury | 1900 |
PublicationDate | 1998-09-01 |
PublicationDateYYYYMMDD | 1998-09-01 |
PublicationDate_xml | – month: 09 year: 1998 text: 1998-09-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | Dordrecht |
PublicationPlace_xml | – name: Dordrecht – name: United States |
PublicationTitle | Cardiovascular drugs and therapy |
PublicationTitleAlternate | Cardiovasc Drugs Ther |
PublicationYear | 1998 |
Publisher | Springer |
Publisher_xml | – name: Springer |
SSID | ssj0007998 |
Score | 1.913496 |
Snippet | The effects of oral treatment with coenzyme Q10 (120 mg/d) were compared for 28 days in 73 (intervention group A) and 71 (placebo group B) patients with acute... |
SourceID | proquest pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 347 |
SubjectTerms | Angina Pectoris - drug therapy Antioxidants - therapeutic use Arrhythmias, Cardiac - drug therapy Biological and medical sciences Cardiovascular system Coenzymes Double-Blind Method Heart Ventricles - drug effects Humans Male Medical sciences Miscellaneous Myocardial Infarction - drug therapy Myocardial Infarction - mortality Myocardial Infarction - prevention & control Myocardium - enzymology Oxidative Stress - drug effects Pharmacology. Drug treatments Placebos Time Factors Ubiquinone - analogs & derivatives Ubiquinone - therapeutic use |
Title | Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction |
URI | https://www.ncbi.nlm.nih.gov/pubmed/9825179 https://search.proquest.com/docview/70068801 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BKiEuFRQqAhT2gHpJjPxYv44talShNoTUEblZu951G5HYVRIfkl_P7PqxNgXxuFiWFSfWzueZ2cl83yD0gQg7hW0HNazESwzCuW1QiISGRwJIdlMmuCm5w9dj73JGPs_duW4bU-ySLfuY7H_JK_kfq8I1sKtkyf6DZZsvhQtwDvaFI1gYjn9l4ynNeL5a7MuCJc8LthQGg8SRD1SvFcuNqhV9CXllOaBDtZGLbL9bicFXyxxobdWa6JbI1oHVDoLcWrFK4EnhbWgM2MgadBpZ-bq43dTtmG2dghuIjap0M9UDnr8pSo0qyevS65RCHnq76NRXb-6K70uV3k6qeizXjL2wLlBUlUZJ0rZNr-N07Ra4SMuDOqUAZxWMnVJJ-IGfb-tNSEEi4lmeWTKou5ra4y_xaHZ1FUcX8-gxOrD90HV76OBsdH4-biK2H6qZyc2D_iQB1foB2ToLC0uXaTn25Pf7EpWfRM_QYbWxwGclSp6jRyI7Qk-uq9aJI3Q6KUXKd0Mcac7dZohP8UTLl-9eoEyjaojbmMIPMYUVpnCe4hpTGDCFFxmuMYUlprDCFNaYwhpTL9FsdBF9ujSqqRxGYgfW1nC5m3qwHoRyx0ukA3dTDpv4hEEu7FAzdUxTUOYH8DGH-cRlDLbJjPmmRYnFmXOMelmeiVcIy7EknEhfQRISBmlIwhR8Q0BtnwSu7fbRSWe14_tSgSWGHBwivN1H7-vVj8Eryr-6aCbyYhP7kvoEyVcfHZdGaW4NAyXS9_qPt75BTzWa36Ledl2IE0hAt-xdhZ8fSSSJaA |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomized%2C+double-blind+placebo-controlled+trial+of+coenzyme+Q10+in+patients+with+acute+myocardial+infarction&rft.jtitle=Cardiovascular+drugs+and+therapy&rft.au=Singh%2C+R+B&rft.au=Wander%2C+G+S&rft.au=Rastogi%2C+A&rft.au=Shukla%2C+P+K&rft.date=1998-09-01&rft.issn=0920-3206&rft.volume=12&rft.issue=4&rft.spage=347&rft.epage=353&rft_id=info:doi/10.1023%2FA%3A1007764616025&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0920-3206&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0920-3206&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0920-3206&client=summon |